TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28238593

Group type: EXPERIMENTAL
Intervention: Lapatinib (1000 mg per day orally) and trastuzumab (loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks intravenously) for 18 weeks; hormone receptor-positive patients received letrozole (2·5 mg per day orally) or tamoxifen (20 mg per day orally).
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lapatinib and trastuzumab in patients with HER2-enriched subtype.
Number of subjects: 151

Group type: COMPARATOR
Intervention: Lapatinib and trastuzumab in patients with non-HER2-enriched subtypes.
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: HER2-enriched subtype identification.
Number of subjects: 151
Study: 28238631

Group type: EXPERIMENTAL
Intervention: 3 doses of QHPV
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 4 doses of QHPV
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 28238701

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subcallosal cingulate
Number of subjects: 16
Study: 28239409

Group type: EXPERIMENTAL
Intervention: Temporary abdominal closure systems (commercial negative pressure)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Commercial negative pressure temporary closure
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Skin closure and Bogotá bag
Number of subjects: 402
Study: 28239472

Group type: EXPERIMENTAL
Intervention: Avelumab, a human IgG1 anti-PD-L1 monoclonal antibody, administered multiple times (exact dosage and duration not specified)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 123
Study: 28239485

Group type: EXPERIMENTAL
Intervention: Digital storytelling approach (DST)
Number of subjects: 0
Study: 28239491

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% fixed-dose combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-blocker monotherapy
Number of subjects: 0
Study: 28240822

Group type: EXPERIMENTAL
Intervention: Recombinant Sfrp3 treatment in myotubes from lean insulin-sensitive subjects
Number of subjects: 41

Group type: COMPARATOR
Intervention: LPS or recombinant IL-6 treatment in in vitro-differentiated myotubes
Number of subjects: 41

Group type: COMPARATOR
Intervention: Skeletal muscle (SkM) Sfrp3 mRNA levels
Number of subjects: 41

Group type: COMPARATOR
Intervention: Serum Sfrp3 levels
Number of subjects: 41

Group type: COMPARATOR
Intervention: Correlation of SkM Sfrp3 mRNA levels
Number of subjects: 41
Study: 28241770

Group type: EXPERIMENTAL
Intervention: Implementation of tobacco use treatment guidelines using the Consolidated Framework for Implementation Research (CFIR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with CHC medical directors, health care providers, and village health workers
Number of subjects: 40
Study: 28241807

Group type: EXPERIMENTAL
Intervention: High-dose external beam radiation therapy (RT)
Number of subjects: 756
Study: 28241824

Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma (PRP) injections and topical application of PRP gel
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma (PRP) injections
Number of subjects: 24
Study: 28241844

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study: 28242046

Group type: EXPERIMENTAL
Intervention: mtDNA content in peripheral blood cells (PBCs)
Number of subjects: 400
Study: 28243404

Group type: EXPERIMENTAL
Intervention: Persumac (prepared from Rhus Coriaria and Bunium Persicum Boiss)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Standard antiemetic therapy for CINV
Number of subjects: 93
Study: 28243468

Group type: EXPERIMENTAL
Intervention: Intravenous abatacept
Number of subjects: 672
Study: 28243577

Group type: EXPERIMENTAL
Intervention: Idursulfase treatment
Number of subjects: 26
Study: 28243592

Group type: EXPERIMENTAL
Intervention: HD Mesh Ablator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cryoballoon pulmonary vein ablation
Number of subjects: 0
Study: 28244573

Group type: EXPERIMENTAL
Intervention: Volunteer mealtime assistants on the intervention ward during weekday lunchtimes
Number of subjects: 407
Study: 28245099

Group type: EXPERIMENTAL
Intervention: Moderate diet-induced weight loss (6% to 8%) in HIV+ women
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Moderate diet-induced weight loss (6% to 8%) in HIV- women
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Moderate diet-induced weight loss (6% to 8%) in both HIV+ and HIV- women
Number of subjects: 28
Study: 28245140

Group type: EXPERIMENTAL
Intervention: Hyperpolarized gas MRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28245821

Group type: EXPERIMENTAL
Intervention: Higher tertiles of GDF-15 (mean GDF-15 was 1,304 pg/mL)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Lower tertile of GDF-15
Number of subjects: 694
Study: 28245880

Group type: EXPERIMENTAL
Intervention: Mobile Stroke Unit (MSU) staffed with anesthesiologists trained in pre-hospital clinical assessment and CT interpretation.
Number of subjects: 2
Study: 28246291

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections, 155 units administered every 12 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 200
Study: 28246307

Group type: EXPERIMENTAL
Intervention: Diabetes group (type 2 diabetes without diabetic retinopathy)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Subjects with resistivity index levels ≤0.7
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 63
Study: 28248551

Group type: EXPERIMENTAL
Intervention: Higher baseline fitness
Number of subjects: 3332

Group type: EXPERIMENTAL
Intervention: Greater cardiopulmonary fitness in young adulthood
Number of subjects: 3332

Group type: EXPERIMENTAL
Intervention: Achieving increased fitness from young adulthood to middle age
Number of subjects: 3332
Study: 28248702

Group type: EXPERIMENTAL
Intervention: Norepinephrine 3, 4, 5, 6, 7, or 8 µg IV bolus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 40
Study: 28248867

Group type: EXPERIMENTAL
Intervention: POAG group
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study: 28249145

Group type: EXPERIMENTAL
Intervention: Lentiviral vector-mediated addition of an antisickling β-globin gene into autologous hematopoietic stem cells; details on dosage and duration not available.
Number of subjects: 1

Group type: COMPARATOR
Intervention: Busulfan conditioning; details on dosage and duration not available.
Number of subjects: 1
Study: 28249726

Group type: EXPERIMENTAL
Intervention: Healthy participants
Number of subjects: 17

Group type: COMPARATOR
Intervention: Patients with cholestasis
Number of subjects: 17
Study: 28249841

Group type: EXPERIMENTAL
Intervention: Bivalent virus-like particle (VLP) vaccine (GI.1/GII.4) administered intramuscularly.
Number of subjects: 0
Study: 28250195

Group type: EXPERIMENTAL
Intervention: Adherence-Specific Social Support
Number of subjects: 0
Study: 28250200

Group type: EXPERIMENTAL
Intervention: Sonic hedgehog (SHh) stimulation in fibroblasts in vitro
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vismodegib (Hh inhibitor) treatment in cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CXCL14 as a systemic biomarker
Number of subjects: 0
Study: 28250201

Group type: EXPERIMENTAL
Intervention: Dog walking
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Grandparenting
Number of subjects: 410
Study: 28250958

Group type: EXPERIMENTAL
Intervention: Herbal trial of Moringa oleifera
Number of subjects: 0
Study: 28251398

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training of the ankle dorsiflexion muscles for 6 weeks
Number of subjects: 0
Study: 28251667

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg single oral dose)
Number of subjects: 22
Study: 28251914

Group type: EXPERIMENTAL
Intervention: Rituximab-based treatment
Number of subjects: 0
Study: 28251936

Group type: EXPERIMENTAL
Intervention: Dietary intake
Number of subjects: 0
Study: 28252528

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg daily
Number of subjects: 252

Group type: COMPARATOR
Intervention: Pravastatin 40 mg daily
Number of subjects: 252
Study: 28252569

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CSM) intervention for 2 months
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 172
Study: 28253270

Group type: EXPERIMENTAL
Intervention: SBRT 50 Gy in 15 fractions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SBRT 45 Gy in 10 fractions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SBRT 42.5 Gy in 5 fractions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 20
Study: 28254122

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT-ON)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Control group (CRT-OFF)
Number of subjects: 610
Study: 28254126

Group type: EXPERIMENTAL
Intervention: CRT-ON (Cardiac Resynchronization Therapy ON)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRT-D (Cardiac Resynchronization Therapy with defibrillator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early CRT-D implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late CRT-D implantation
Number of subjects: 0
Study: 28254128

Group type: EXPERIMENTAL
Intervention: HeartLogic multisensor index and alert algorithm
Number of subjects: 900
Study: 28254177

Group type: EXPERIMENTAL
Intervention: Clinical and biomarker scoring system
Number of subjects: 649
Study: 28254179

Group type: EXPERIMENTAL
Intervention: Neutrophil counts 6 to 7 × 10
Number of subjects: 775231

Group type: COMPARATOR
Intervention: Neutrophil counts 2 to 3 × 10
Number of subjects: 775231
Study: 28254203

Group type: EXPERIMENTAL
Intervention: Specialty care
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Minimal caregiver worry about medication adverse effects
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Positive sensitization to ragweed allergen
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Negative specific IgE for dust mite
Number of subjects: 222
Study: 28254736

Group type: EXPERIMENTAL
Intervention: High disease activity group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low disease activity group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Muscle strength measured with dynamometer for isometric hand grip strength and quadriceps femoris muscle contraction strength
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Functional ability and frailty evaluated with self-reported questionnaires and physical tests
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sleep quality measured with Medical Outcomes Study Sleep Scale
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sexual functioning assessed with self-reported questionnaires
Number of subjects: 100
Study: 28254767

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28254869

Group type: EXPERIMENTAL
Intervention: Selective radiotherapy dose increase to hypoxic tumor areas, details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 28255448

Group type: COMPARATOR
Intervention: Passive techniques (mobilisations and inbed cycle ergometry)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electrostimulation of the quadriceps muscle and Functional Electrical Stimulation-cycling (FES-cycling)
Number of subjects: 20
Study: 28255449

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) plus methotrexate (MTX)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: DAS28-CRP
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: DAS28-CRP and DAS28-ESR
Number of subjects: 833
Study: 28255524

Group type: EXPERIMENTAL
Intervention: CC-122
Number of subjects: 3
Study: 28256358

Group type: COMPARATOR
Intervention: MVA vaccine subcutaneously by S&N on Days 1 and 29 (standard)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MVA vaccine subcutaneously by S&N on Days 1 and 15
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MVA vaccine subcutaneously by S&N on Days 1 and 22
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MVA vaccine subcutaneously by JI on Days 1 and 29
Number of subjects: 100
Study: 28257145

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28257413

Group type: EXPERIMENTAL
Intervention: Topological data analysis (TDA)
Number of subjects: 586
Study: 28257602

Group type: EXPERIMENTAL
Intervention: Temporary steroids while background immunosuppressants were withdrawn
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Standard therapy resumed when symptoms recurred
Number of subjects: 41
Study: 28257793

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28258250

Group type: EXPERIMENTAL
Intervention: MRI ventilation abnormalities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT biomarkers of COPD
Number of subjects: 0
Study: 28258392

Group type: EXPERIMENTAL
Intervention: Propofol clearance based on total body weight (TBW)
Number of subjects: 20
Study: 28258416

Group type: EXPERIMENTAL
Intervention: CTC-positive patients
Number of subjects: 140

Group type: COMPARATOR
Intervention: CTC-negative patients
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: N0 group
Number of subjects: 140

Group type: COMPARATOR
Intervention: N+ group
Number of subjects: 140
Study: 28258737

Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin
Number of subjects: 7831

Group type: COMPARATOR
Intervention: No prophylactic indomethacin
Number of subjects: 7831
Study: 28259055

Group type: EXPERIMENTAL
Intervention: Childhood-onset craniopharyngioma patients with hypothalamic tumor involvement
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study: 28259057

Group type: EXPERIMENTAL
Intervention: 3-oz water swallowing test (3-WST)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Speech language pathologist's recommendation for altered diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Speech language pathologist's recommendation for nil per os (nothing by mouth)
Number of subjects: 45
Study: 28259424

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2867
Study: 28259577

Group type: EXPERIMENTAL
Intervention: Fenestrated and branched endovascular repair
Number of subjects: 100
Study: 28259750

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) to 50 Gy in four fractions
Number of subjects: 59
Study: 28260539

Group type: EXPERIMENTAL
Intervention: Advancing Caregiver Training (ACT) intervention
Number of subjects: 110
Study: 28261276

Group type: EXPERIMENTAL
Intervention: Dietary intake of selenium and methyl donor nutrients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intake of methyl donating nutrients including folate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Higher levels of LINE-1 methylation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intake of selected dietary nutrients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IFNγ promoter CpG site -186
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IFNγ promoter CpG sites
Number of subjects: 32
Study: 28261500

Group type: EXPERIMENTAL
Intervention: Wii-Fit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28261651

Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg daily + Cisplatin 75 mg/m²
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cisplatin and Pazopanib
Number of subjects: 35
Study: 28261656

Group type: EXPERIMENTAL
Intervention: BIW-8962 (monoclonal antibody to GM2 ganglioside)
Number of subjects: 0
Study: 28261896

Group type: EXPERIMENTAL
Intervention: simplified Vancouver Chest Pain Rule (sVCPR)
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: simplified Emergency Department Assessment of Chest Pain Score (sEDACS) ≥ 3
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: Accelerated Diagnostic protocol to Assess Patients with chest pain using contemporary troponins (ADAPT-ADP)
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: simplified Emergency Department Assessment of Chest Pain Score (sEDACS) with cut-point score of 4
Number of subjects: 1081
Study: 28262342

Group type: EXPERIMENTAL
Intervention: Aspirin + dipyrone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 72
Study: 28262584

Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) - 30 Gy in five fractions delivered with IMRT technique
Number of subjects: 520

Group type: COMPARATOR
Intervention: Whole breast irradiation (WBI) - 50 Gy in 25 fractions plus a 10 Gy boost on tumour bed
Number of subjects: 520
Study: 28262724

Group type: EXPERIMENTAL
Intervention: Combined androgen block (CAB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GnRH agonist monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAB and GnRH
Number of subjects: 0
Study: 28263938

Group type: EXPERIMENTAL
Intervention: Random forests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boosting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Logistic Regression (LR)
Number of subjects: 0
Study: 28264059

Group type: EXPERIMENTAL
Intervention: HS-CRP
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PCT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PCT cut-off value
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TNF-α and GM-CSF
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: WBC
Number of subjects: 25
Study: 28264616

Group type: EXPERIMENTAL
Intervention: Romidepsin
Number of subjects: 95
Study: 28264614

Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 16
Study: 28264648

Group type: EXPERIMENTAL
Intervention: Selumetinib plus docetaxel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Selumetinib plus dacarbazine
Number of subjects: 60
Study: 28264723

Group type: EXPERIMENTAL
Intervention: Prenatal environment (including maternal adiposity, smoking, blood glucose, plasma unsaturated fatty acid levels)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores derived from genetic association studies on adult adiposity
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Neonatal methylation markers from seven gene loci (ANK3, CDKN2B, CACNA1G, IGDCC4, P4HA3, ZNF423, MIRLET7BHG)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Methylation levels at three of seven birth weight-linked loci
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Six birth weight-linked loci
Number of subjects: 987
Study: 28264792

Group type: EXPERIMENTAL
Intervention: Mobile Health Care Environment with tailored behavioral messaging
Number of subjects: 0
Study: 28264796

Group type: EXPERIMENTAL
Intervention: Jawbone Up24 monitor, tablet with Jawbone Up app, brief weekly telephone counseling for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 40
Study: 28264825

Group type: EXPERIMENTAL
Intervention: Psychological factors (pain catastrophising, kinesiophobia, self-efficacy)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Pain catastrophising and kinesiophobia
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Predictive measures (kinesiophobia, pain catastrophising, anxiety, depression, etc.)
Number of subjects: 307
Study: 28264833

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment (AC)
Number of subjects: 28624

Group type: COMPARATOR
Intervention: No anticoagulant treatment (no AC)
Number of subjects: 28624
Study: 28264845

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (6-day treatment)
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Linezolid (10-day treatment)
Number of subjects: 1333
Study: 28264892

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 28265009

Group type: EXPERIMENTAL
Intervention: EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA) at 5 concentrations
Number of subjects: 0
Study: 28265415

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 17

Group type: COMPARATOR
Intervention: Smaller pudding volume in diabetic non-surgical subjects
Number of subjects: 17
Study: 28265448

Group type: EXPERIMENTAL
Intervention: Hot Weather Infantry Boots (HWIB)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Newly Designed Israeli Infantry Boots (NDIB)
Number of subjects: 205
Study: 28265459

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetrabenazine
Number of subjects: 0
Study: 28265478

Group type: EXPERIMENTAL
Intervention: Twice-daily pramipexole extended release (PER) regimen
Number of subjects: 44

Group type: COMPARATOR
Intervention: Once-daily pramipexole extended release (PER) regimen
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Comparison of both regimens
Number of subjects: 44
Study: 28265757

Group type: EXPERIMENTAL
Intervention: Frozen section analysis
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: OSCAR-Endo score
Number of subjects: 304
Study: 28265861

Group type: EXPERIMENTAL
Intervention: Human urinary kallidinogenase (HUK) administered by intravenous drip once daily for 21 consecutive days
Number of subjects: 2186
Study: 28266092

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine (3 doses at 0, 1, and 6 months)
Number of subjects: 3084
Study: 28268087

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT; acetylsalicylic acid [ASA] + ADP receptor inhibitor [ADPri], mainly clopidogrel)
Number of subjects: 9225

Group type: EXPERIMENTAL
Intervention: Antithrombotic drug (most commonly ASA)
Number of subjects: 9225

Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 9225

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 9225
Study: 28268134

Group type: EXPERIMENTAL
Intervention: Poorly controlled asthma
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Limited physical activity
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Very poorly controlled asthma symptoms
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Activity limitation
Number of subjects: 324
Study: 28268358

Group type: EXPERIMENTAL
Intervention: EDA-Gram representation of electrodermal activity (EDA) signals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Derived features from EDA-Gram
Number of subjects: 0